KEGG   DRUG: D09207Help
Entry
D09207                      Drug                                   

Name
Catumaxomab (INN);
Removab (TN)
Activity
Monoclonal antibody
Remark
ATC code: 
Comment
anti-EpCAM and anti-CD3 monoclonal antibody
trifunctional antibody
Indication: Malignant ascites
Target
EpCAM [HSA:4072] [KO:K06737];
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
hsa04640  Hematopoietic cell lineage
hsa04660  T cell receptor signaling pathway  
 
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC09 Catumaxomab
      D09207  Catumaxomab (INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD326 (EpCAM) [HSA:4072] [KO:K06737]
    Catumaxomab [ATC:L01XC09]
     D09207  Catumaxomab (INN)
  T-cell co-receptor
   CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
    Catumaxomab [ATC:L01XC09]
     D09207  Catumaxomab (INN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Catumaxomab [ATC:L01XC09]
    D09207  Catumaxomab (INN)
BRITE hierarchy
Other DBs
CAS: 
509077-98-9
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system